Oxandrolone - FDA prescribing information, side effects and uses

Oxandrolone

oxandrolone hepatotoxicity

Patients may present with right upper quadrant discomfort and hepatomegaly or with sudden abdominal pain and vascular collapse due to hepatic rupture and hemoperitoneum. Hepatotoxicity associated with dietary supplements containing anabolic steroids. Signs of virilization deepening voice, hirsutism, acne, clitoromegaly ; urine and serum calcium in women with breast cancer. The original brand name of oxandrolone was Anavar, which was marketed in the United States and the Netherlands. Ma Huang has also been implicated in cases of drug induced liver injury, but is associated with an acute hepatocellular pattern of injury.

Dosage Forms

Therapy should be intermittent. Certain clinical effects and adverse reactions demonstrate the androgenic properties of this class of drugs. Danazol and cholestatic hepatitis. Benign liver-cell adenoma associated with long-term administration of an androgenic-anabolic steroid methandienone. To view content sources and attributions, please refer to our editorial policy.

Peliosis hepatis, a condition in which liver and, sometimes, splenic tissue is replaced with blood-filled cysts, has occurred in patients receiving androgenic anabolic steroids. These cysts are sometimes present with minimal hepatic dysfunction and have been associated with liver failure. Often, they are not recognized until life-threatening liver failure or intra-abdominal hemorrhage develops.

Withdrawal of drug usually results in complete disappearance of lesions. Most often these tumors are benign and androgen-dependent, but fatal malignant tumors have occurred.

Withdrawal of drug often results in regression or cessation of tumor progression. However, hepatic tumors associated with androgens or anabolic steroids are much more vascular than other hepatic tumors and may be silent until life-threatening, intra-abdominal hemorrhage develops. Blood lipid changes associated with increased risk of atherosclerosis are seen in patients treated with androgens and anabolic steroids. The changes may be very marked and could have a serious impact on the risk of atherosclerosis and coronary artery disease.

May cause blood lipid changes with increased risk of arteriosclerosis. Anabolic steroids may cause peliosis hepatis or liver cell tumors which may not be apparent until liver failure or intra-abdominal hemorrhage develops. Discontinue in case of cholestatic hepatitis with jaundice or abnormal liver function tests.

Use with caution in patients with hepatic impairment. Use with caution in patients with breast cancer; may cause hypercalcemia by stimulating osteolysis. Discontinue use if hypercalcemia occurs. May have adverse effects on glucose tolerance; use caution in patients with diabetes.

Use with caution in patients with conditions influenced by edema eg, cardiovascular disease, migraine, seizure disorder, renal impairment ; may cause fluid retention. Use caution with concomitant warfarin therapy; warfarin dose may need to be significantly decreased. Use with caution in elderly patients, they may be at greater risk for prostatic hyperplasia, prostate cancer, fluid retention, and transaminase elevations. May accelerate bone maturation without producing compensatory gain in linear growth in children; effect may continue for 6 months after the drug is stopped; in prepubertal children perform radiographic examination of the left hand and wrist every 6 months to determine the rate of bone maturation and to assess the effect of treatment on the epiphyseal centers.

May cause mild virilization in females; monitor for signs of virilization deepening of the voice, hirsutism, acne, clitoromegaly. Discontinue with evidence of mild virilization in female patients; early discontinuation may prevent irreversible virilization. Signs of virilization deepening voice, hirsutism, acne, clitoromegaly ; urine and serum calcium in women with breast cancer.

Use is contraindicated in women who are or may become pregnant; masculinization of the fetus has been reported. During this hospital stay, were you given any medicine that you had not taken before?

Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?

Have patient report immediately to prescriber signs of high calcium weakness, confusion, fatigue, headache, nausea and vomiting, constipation, or bone pain , signs of liver problems dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or jaundice , priapism, acne, severe anxiety, bruising, bleeding, testicular changes, signs of virilization in females a deep voice, facial hair, acne, or menstrual changes , enlarged breasts, bladder irritation, depression, shortness of breath, excessive weight gain, or swelling of arms or legs HCAHPS.

This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions. Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. Like other AAS, oxandrolone may worsen hypercalcemia by increasing osteolytic bone resorption.

Women who are administered oxandrolone may experience virilization , irreversible development of masculine features such as voice deepening , hirsutism , menstruation abnormalities , male-pattern hair loss , and clitoral enlargement. Unlike some AAS, oxandrolone does not generally cause gynecomastia because it is not aromatized into estrogenic metabolites.

Oxandrolone greatly increases warfarin 's blood-thinning effect, sometimes dangerously so. Compared to testosterone and many other AAS, oxandrolone is less androgenic relative to its strength as an anabolic. Oxandrolone was first made by Raphael Pappo and Christopher J. Jung while at Searle Laboratories now part of Pfizer. The researchers first described the drug in The original brand name of oxandrolone was Anavar, which was marketed in the United States and the Netherlands.

Among those using oxandrolone for non-medical purposes, it is often referred to colloquially as "Var", a shortened form of the brand name Anavar. Outside of the United States, the availability of oxandrolone is quite limited. Oxandrolone is sometimes used as a doping agent in sports. There are known cases of doping in sports with oxandrolone by professional athletes. From Wikipedia, the free encyclopedia. S Hemat 2 March Handbook of Drug Interactions: A Clinical and Forensic Guide.

A systematic review and meta-analysis". Expert Opinion on Pharmacotherapy. International Journal of Sports Medicine. United States Food and Drug Administration. Retrieved 17 June Food and Drug Administration. Retrieved 21 June Current Allergy and Asthma Reports. Clinics in Liver Disease. Evidence from Recent Studies and Recommendations for Use". Hormone Research in Paediatrics.

Expert Opinion on Emerging Drugs. Aronson 21 February Journal of Pediatric Endocrinology and Metabolism. Retrieved 20 June Safety Alerts for Human Medical Products. In Katzung, Bertram G.

Iamges: oxandrolone hepatotoxicity

oxandrolone hepatotoxicity

Benavidez 26 February J Am Osteopath Assoc ;

oxandrolone hepatotoxicity

The Effects of Drugs.

oxandrolone hepatotoxicity

Excipient information presented when available limited, particularly for generics ; consult specific steroids using paypal oxandrolone hepatotoxicity. Serum determination of lipid levels should be performed oxandrolone hepatotoxicity oxandrolonf therapy adjusted accordingly. Journal of Pediatric Endocrinology and Metabolism. Use is contraindicated in women who are or may become pregnant; masculinization of the fetus has been reported. Use of corticosteroids is usually ineffective and should be avoided. This adverse effect results in compromised adult height.